Lexaria Bioscience Corp. (NASDAQ:LEXX) Stock Short Interest Climbs 402.2%

Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 179,002 shares, a growth of 402.2% from the August 31st total of 35,644 shares. Approximately 11.8% of the company’s shares are sold short. Based on an average daily volume of 110,136 shares, the short-interest ratio is currently 1.6 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.50.

Get Lexaria Bioscience alerts:

Get Our Latest Report on LEXX

Lexaria Bioscience Stock Performance

Shares of Lexaria Bioscience stock opened at $3.44 on Friday. Lexaria Bioscience has a 52-week low of $2.80 and a 52-week high of $23.25. The stock has a market capitalization of $5.67 million, a price-to-earnings ratio of -0.67 and a beta of 0.50. The company’s 50 day moving average price is $7.82 and its 200-day moving average price is $9.63.

Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last posted its quarterly earnings results on Monday, July 13th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). As a group, equities research analysts forecast that Lexaria Bioscience will post -4.05 earnings per share for the current fiscal year.

About Lexaria Bioscience

(Get Free Report)

Lexaria Bioscience Corp. is a biotechnology company developing drug-delivery technologies designed to improve the absorption and delivery of orally administered active compounds. Its proprietary DehydraTECH platform is intended to enhance bioavailability and may facilitate the delivery of certain compounds across biological barriers, including the blood-brain barrier.

The company has researched DehydraTECH applications involving cannabinoids, nicotine, non-steroidal anti-inflammatory drugs, antiviral compounds and other active pharmaceutical ingredients.

See Also

• Five stocks we like better than Lexaria Bioscience
• NVIDIA’s Next AI Chip Ramp Could Open the Door to Another Major Stock Move
• Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the Test
• Cintas Raises Guidance as a Major Catalyst Moves Closer
• 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market

Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.